Search interest in “Neutrogena stock” has picked up, but there’s no separate Neutrogena ticker. Neutrogena is a brand within Kenvue, which trades as KVUE on the NYSE. Kenvue’s product lineup includes Tylenol, Listerine, Aveeno, Band‑Aid, Nicorette, and several other consumer health names.
So KVUE offers the closest public exposure to Neutrogena — though the brand is only one part of a diversified business. And currently, Kenvue’s stock price is influenced as much by its pending acquisition by Kimberly‑Clark as by skincare sales.
Is There a Neutrogena Stock Symbol?
Neutrogena does not have its own stock symbol. The brand was previously part of Johnson & Johnson. In 2023, Johnson & Johnson completed the separation of its consumer health business into Kenvue, transferring brands including Neutrogena, Tylenol, Aveeno and Listerine to the new company.
Kenvue now trades as NYSE: KVUE. Johnson & Johnson, which trades as JNJ, is focused on pharmaceuticals and medical technology and is no longer the direct owner of Neutrogena.
Investors searching for Neutrogena stock should therefore look at Kenvue. They should not assume, however, that buying KVUE is a pure investment in the skincare brand. Kenvue operates across self-care, skin health and beauty, and essential health products in more than 165 countries.
Why Is KVUE Different From a Normal Consumer Stock Right Now?
Kenvue is in the middle of a takeover by Kimberly-Clark, the company behind brands such as Kleenex, Huggies, Cottonelle and Kotex.
Under the agreed terms, Kenvue shareholders are expected to receive $3.50 in cash and 0.14625 Kimberly-Clark shares for every KVUE share they own when the transaction closes.
The deal was announced in November 2025 and later approved by shareholders of both companies. Kenvue said in its latest earnings release that it expects the combination to close in the fourth quarter of 2026, subject to regulatory approvals and the remaining closing conditions.
This arrangement changes how KVUE trades. Most of the consideration is being paid in Kimberly-Clark shares, so the implied value of Kenvue moves with KMB stock.
At the August 18 closing prices, KVUE traded near $18.80 while Kimberly-Clark was around $107.72. Applying the merger formula produced an implied value of approximately $19.25 per KVUE share:
$3.50 + (0.14625 × $107.72) = approximately $19.25
That left a gap of roughly 2.4% between Kenvue’s market price and the implied deal value. The calculation changes whenever KMB moves.
The gap is not free money. It reflects the time until closing, regulatory uncertainty, possible changes in market conditions and the risk that the transaction is delayed or fails to close. Investors also need to consider that the shares they are due to receive may be worth more or less by the time the acquisition is completed.
How Is Neutrogena Performing?
Neutrogena sits within Kenvue’s Skin Health and Beauty segment, alongside brands including Aveeno and OGX.
That segment was one of Kenvue’s stronger businesses in the second quarter of 2026. Net sales increased 5.1% from the previous year, while organic sales rose 3.7%. Volume increased 1.0%, and the company reported organic growth across every geographic region.
Kenvue credited face care, hair care, e-commerce execution and new products for the improvement. Neutrogena Ultra Sheer Sun was among the innovations management identified as contributing to the segment’s performance.
The broader company also returned to modest growth. Kenvue reported a 3.0% increase in second-quarter net sales and organic growth of 1.6%. Diluted earnings per share increased from $0.22 to $0.24, while adjusted EPS rose from $0.29 to $0.31.
Those figures suggest that Neutrogena remains commercially important and that the wider Kenvue portfolio is moving in a better direction after a difficult period.
The improvement was not clean across every measure. Kenvue’s gross margin declined from 58.9% to 58.2%, and its adjusted operating margin fell from 22.7% to 22.1%. Higher brand investment and other operating costs partly offset the benefit of sales growth and restructuring savings.
Kenvue has also stopped providing forward guidance because of the pending Kimberly-Clark transaction. That leaves investors with less visibility into the company’s expected standalone performance.
Why Is Neutrogena Facing Brand Backlash?
Some of the recent attention around Neutrogena has come from renewed discussion of the brand’s former relationship with actress Hayden Panettiere.
Panettiere said that Neutrogena attempted to end its long-running endorsement relationship with her after she spoke publicly about postpartum depression in 2015. According to her account, her representative challenged the proposed termination, the existing contract continued, and the brand did not renew it when it expired.
Neutrogena has not publicly confirmed the full account. The claim should therefore be described as Panettiere’s version of events rather than an established finding about the company’s conduct.
The timing also matters. In 2015, Neutrogena was owned by Johnson & Johnson. Kenvue did not become an independent company until 2023. The current business inherited the brand, but it was not the listed parent at the time of the alleged contract dispute.
Social-media users have called for a boycott, creating a reputational issue for the brand. There is not yet enough public evidence to measure its commercial impact. Kenvue does not report Neutrogena’s revenue separately, and the latest quarterly results predate the recent wave of online criticism.
KVUE closed almost unchanged on August 18. That does not prove the controversy is unimportant, but it does mean there is no clear evidence yet of a large stock-market reaction tied specifically to the backlash.
What Could Move Kenvue Stock Next?
Until the acquisition closes, KVUE is likely to remain closely connected to KMB.
A rise in Kimberly-Clark shares increases the value of the stock component promised to Kenvue shareholders. A decline has the opposite effect. Merger approvals, regulatory developments and any change to the expected fourth-quarter timetable may also move the spread between KVUE’s market price and the implied consideration.
Kenvue’s operating performance still matters. Stronger skincare demand, successful product launches and continued e-commerce growth could support confidence in the assets Kimberly-Clark is acquiring. Weak consumer demand, margin pressure or a deterioration in major brands would make the expected synergies harder to achieve.
Brand reputation is another variable. Online criticism does not automatically lead to lower sales, but a sustained boycott that reaches retailers or changes purchasing behavior could become financially relevant. Investors would need evidence from market-share data, retailer commentary or future segment results before drawing that conclusion.
Final Thoughts
“Neutrogena stock” is useful as a search term, but it is not an accurate description of what investors can buy.
The relevant security is Kenvue, and Kenvue represents a diversified consumer health portfolio rather than one skincare brand. Its latest results show that Skin Health and Beauty is growing, with Neutrogena contributing through sun-care innovation and e-commerce demand.
For the next several months, however, KVUE will largely be a merger-linked stock. Its price will reflect Kimberly-Clark’s market value, the probability of completing the acquisition and the time remaining until closing.
Neutrogena’s commercial momentum and public reputation still matter, but they sit inside a larger transaction. Anyone researching KVUE should follow both sides of the story: how the brands are performing and whether the Kimberly-Clark deal remains on schedule.
Readers can follow global stock and crypto market coverage through Tapbit. Existing users can log in here, while new users can create an account.
Frequently Asked Questions
Does Neutrogena have a stock?
No. Neutrogena is a brand rather than a separately listed company. It does not have its own stock symbol.
What is the Neutrogena stock symbol?
The closest related stock is Kenvue, which trades on the New York Stock Exchange under the symbol KVUE.
Who owns Neutrogena?
Neutrogena is owned by Kenvue. Kenvue also owns Tylenol, Aveeno, Listerine, Band-Aid, Nicorette and other consumer health brands.
